Industry N Nature Medicine
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry N Nature Medicine
Industry
Nature Reviews Drug Discovery
Industry N Nature Medicine
Industry N Nature Biomedical Engineering
Industry N Nature Biomedical Engineering
Industry N Nature Biomedical Engineering
Industry N Nature Biomedical Engineering
Industry
BioCentury
BIOCENTURY | DISCOVERY & TRANSLATIONFULLY AUTONOMOUS LABS NEED HUMAN KNOW-HOW, NOT JUST MORE ROBOTSAstraZeneca, Thermo Fisher, and Sofinnova Partners on capturing bench expertise to enable better experiments and less human intervention
Industry
TechCrunch Biotech and Health
Intero Biosystems is selling lab-grown human intestines to drugmakers as regulators push for alternatives to animal testing, while the startup looks to scale production and expand its organoid technology.
Industry
MedCity News
Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset.…
Industry
TechCrunch Biotech and Health
German startup TimeTeller has developed a saliva test kit to help anyone understand their circadian rhythm; it aims to reduce side effects from cancer treatments.
Industry
Inside Precision Medicine
A mobile website that delivers tailored messages and the use of motivational telephone calls can both encourage people to undergo hereditary cancer genetic testing, emphasizing the importance of how delivering health messages can improve update. The post Cancer Genetic Testing Up…
Industry
Inside Precision Medicine
A study of 18,476 participants identified two metabolomic aging metrics that showed that people whose metabolomic age exceeded their chronological age had higher risks of chronic disease and death than those with lower metabolic age acceleration. The post Metabolomic Aging Clock…
Industry
Fierce Biotech
Immune Boost Capital Invests in Orthrus Therapeutics to Advance Antigen-Specific Immune Tolerance for Autoimmune Disease pesurya Wed, 10/14/2026 - 13:42
Industry P Pharmaceutical Commerce
GEODIS' David Frouin explains why quick packaging qualification, backups on every lane and actionable IoT data underpin cold chain resilience.
Industry P Pharmaceutical Executive
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Industry
GEN
By analyzing maternal sera from term and preterm pregnancies, in combination with studies in live mice and in human placental tissues, researchers identified antibodies that play a role in triggering early labor. The post Preterm Birth for Some Women Linked to Specific Autoantibo…
Industry
GEN
Deep eutectic solvents can modulate multiple biocatalysis process parameters, thus minimizing or eliminating the need for bioengineering in certain enzymes while enhancing productivity and product quality. The post For Biocatalysis, Solvents are a Key Bioprocessing Parameter appe…
Industry
GEN
Splitting lipid nanoparticle manufacturing into multiple mixing steps can help better control the size, shape, and stability of particles, with the aim of improving product quality during commercial-scale production. The post Turning Process Understanding Into Control of Lipid Na…
Industry
GEN
Shorter cell expansion steps could significantly accelerate CAR T-cell therapy production processes, according to researchers, who cite microfluidic culture systems, real-time PAT tools, and AI-enabled predictive models as key enablers of this new rapid manufacturing paradigm. Th…
Industry
BioPharma Dive
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.
Industry
TechCrunch Biotech and Health
Get 50% discount on the last two days of TechCrunch Disrupt 2026, Oct. 14-25, in San Francisco's Moscone West. Register now and join the rest of the startup ecosystem. Today, it's all about physical and software AI.
Industry
Inside Precision Medicine
An engineered CRISPR Cas13a enzyme can detect RNA with 100 times greater sensitivity than its original version. The post CRISPR-Based Test Improves Detection of HIV and Other RNA Viruses appeared first on Inside Precision Medicine.
Industry
Inside Precision Medicine
Researchers discovered that prolonged physical confinement activates a molecular pathway that restricts cancer cell movement and triggers cell death, revealing a potential new way to predict metastatic risk and prevent cancer spread. The post Mechanical Pressure Triggers Cancer C…
Industry
MedTech Dive
In a strategy shift, the company will invest in its procedural ultrasound business, supporting cardiovascular surgeries
Industry
BioPharma Dive
Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.
Industry
Inside Precision Medicine
Tiny magnetic robots could eventually bring chemotherapy directly to tumors in the liver, pancreas, and brain. Researchers envision interchangeable modules capable of delivering repeated doses or combinations of cancer therapies. The post Magnetic Millirobots Could Deliver Cancer…
Industry
Inside Precision Medicine
Single-cell and spatial transcriptomics reveal genetically distinct cancer cell populations within pancreatic tumors, some of which may contribute disproportionately to disease progression and treatment resistance. The post Single-Cell Profiling Exposes Hidden Diversity Within Pa…
Industry
TechCrunch Biotech and Health
Day 2 at TechCrunch Disrupt 2026, full of all themes across AI, investor-only session, more roundtables, and more. Register to save 50% on your pass.
Industry P pharmaphorum
GSK planning 1,200 job cuts in Belgium, says paper Phil.Taylor Wed, 14/10/2026 - 14:08
Industry B BioPharm International
Gilead will develop up to three PRO-XTEN T-cell engagers discovered by Vir Biotechnology for solid tumors in a deal worth up to $1.74 billion.
Industry P PLOS Biology
by Shiying Liu, Shi-Yan Ng Neuroinflammation and vascular dysfunction are hallmarks of most neurodegenerative diseases. For organoids intended to model neurodegeneration, immune, and vascular cells should therefore be considered fundamental components, rather than optional additi…
Industry P PLOS Biology
by Xiao Peng Liu, Xiao Zhang, Chun Xia Cai, Miao Miao Qin, Xiang Kai Leng, Jia Hao Chen, Yi Fan Han, Jun Ying Xiao, Jia He Huang, Jiang Wei Wu Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality, yet its underlying mechanism remains elusive. Here,…
Industry P PLOS Biology
by James Matthew Ragle, Murugesan Pooranachithra, Guinevere E. Ashley, Emma Cadena, Batia Blank, Katelyn Kang, Cincy Chen, Aditree R. Bhowmick, Soraya H. Mercado, Tabatha E. Wells, John C. Clancy, Andrew D. Chisholm, Jordan D. Ward Barrier epithelia are shielded from the external…
Industry P PLOS Biology
by Hanyu Fu, Zhiqiu Liu, Jingwei Zhou, Luyao Zhang, Cai Liu, Dewei Tang, Shuangshuang Zhang, Anan Li, Dejuan Wang Social learning is a fundamental adaptive strategy that critically shapes decision-making and feeding behaviors. Through the social transmission of food preference (S…
Industry P Pharmaceutical Commerce
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains why validation, change management and stakeholder alignment now drive automation projects.
Industry
Fierce Biotech
From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2 jpiatt Wed, 10/14/2026 - 09:40
Industry P Pharmaceutical Executive
Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Industry P pharmaphorum
From bedside to breakthroughs: Reimagining the human experience in healthcare Nicole.Raleigh Wed, 14/10/2026 - 13:34
Industry
BioPharma Dive
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.